Aptose Biosciences announced on May 29, 2026 [1], a revised timeline for the closing of its plan of arrangement with Hanmi Pharmaceutical [1].
The update comes as the companies work to finalize a merger that would integrate Aptose into Hanmi's corporate structure. This arrangement involves Hanmi Pharmaceutical Co. Ltd. and its subsidiary, HS North America Ltd. [1].
The company, which trades under the ticker TSX: APS [3], issued the update to inform investors and stakeholders of the adjusted expectations for the closing date [2]. While the specific new date was not detailed in the announcement, the company said that the plan of arrangement remains the intended path forward [1].
However, the pending merger coincides with reports of financial instability at the company. According to separate reporting, Aptose has faced a cash crunch that led it to exit a previous pact regarding a blood-cancer drug candidate [4]. In that earlier deal, Aptose had paid $2 million to exercise its option on the candidate [4].
Reports suggest that the buyout by Hanmi may have blocked the development of that specific drug, contributing to the company's decision to exit the pact [4]. This creates a contrast between the official corporate timeline for the merger and the operational challenges facing the company's pipeline.
The company maintains its headquarters in San Diego, California, and Toronto, Ontario [2].
“Aptose announced a revised timeline for the closing of its plan of arrangement with Hanmi Pharmaceutical.”
The disconnect between Aptose's official merger updates and reports of a cash crunch suggests a volatile transition period. While the plan of arrangement with Hanmi Pharmaceutical remains the primary objective, the abandonment of a blood-cancer drug candidate indicates that the company may be sacrificing its research pipeline to ensure the merger reaches completion.
